Cantor Fitzgerald Has Positive View of CATX FY2025 Earnings

Perspective Therapeutics, Inc. (NYSE:CATX) – Equities researchers at Cantor Fitzgerald upped their FY2025 earnings estimates for Perspective Therapeutics in a report released on Tuesday, May 13th. Cantor Fitzgerald analyst L. Watsek now expects that the company will earn ($1.04) per share for the year, up from their previous forecast of ($1.09). Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share.

Other analysts have also issued reports about the stock. Scotiabank started coverage on shares of Perspective Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price target for the company. Brookline Capital Management upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a report on Monday, March 10th. Royal Bank of Canada dropped their target price on shares of Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Thursday, March 27th. Lifesci Capital upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a report on Thursday, March 6th. Finally, Wedbush reiterated an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a report on Tuesday. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $12.50.

Perspective Therapeutics Stock Performance

NYSE CATX opened at $2.63 on Thursday. The company has a 50-day simple moving average of $2.24 and a two-hundred day simple moving average of $3.70. Perspective Therapeutics has a 12-month low of $1.60 and a 12-month high of $16.90.

Hedge Funds Weigh In On Perspective Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in CATX. Y Intercept Hong Kong Ltd bought a new position in shares of Perspective Therapeutics during the fourth quarter valued at approximately $33,000. Aigen Investment Management LP bought a new position in shares of Perspective Therapeutics during the fourth quarter valued at approximately $34,000. National Bank of Canada FI increased its stake in shares of Perspective Therapeutics by 549,900.0% during the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock valued at $35,000 after purchasing an additional 10,998 shares in the last quarter. ProShare Advisors LLC increased its stake in shares of Perspective Therapeutics by 49.1% during the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock valued at $49,000 after purchasing an additional 5,011 shares in the last quarter. Finally, Vontobel Holding Ltd. bought a new position in shares of Perspective Therapeutics during the fourth quarter valued at approximately $51,000. Institutional investors own 54.66% of the company’s stock.

Insider Buying and Selling

In related news, Director Robert F. Williamson III purchased 38,145 shares of the firm’s stock in a transaction that occurred on Monday, March 31st. The stock was bought at an average cost of $2.14 per share, with a total value of $81,630.30. Following the completion of the purchase, the director now directly owns 108,982 shares in the company, valued at approximately $233,221.48. This represents a 53.85% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Juan Graham purchased 33,333 shares of the firm’s stock in a transaction that occurred on Friday, March 28th. The stock was bought at an average cost of $2.25 per share, with a total value of $74,999.25. Following the completion of the purchase, the chief financial officer now owns 35,354 shares of the company’s stock, valued at $79,546.50. This represents a 1,649.33% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 115,696 shares of company stock valued at $256,344 over the last three months. Corporate insiders own 3.72% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.